Clinical trials: Breast Cancer, Breast Neoplasms
Triple Negative Breast Cancer
Huaier Granule in Treating Women With Triple Negative Breast Cancer
RATIONALE: Huaier (Trametes robiniophila Murr) is a traditional Chinese medicine, which has been widely used in China for many years.
- Trial name
- NCT02615457
- Testing
- Huaier Granule
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shandong University
Disorders of Breast
High-Intensity Interval Training for Women at Heightened Risk for Breast Cancer
The goal of this research study is to learn if there is a level of exercise training that is more effective in lowering biomarker levels that are linked to breast cancer risk.
- Trial name
- NCT02923401
- Testing
- Exercise, Questionnaires, Motivational Session
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
HER2 Positive Breast Cancers
A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer
The purpose of this study is to determine the maximal tolerated dose (MTD) or recommended dose (RD) and to assess the safety and tolerability of tucatinib (ONT-380) combined with ado-trastuzumab emtansine (T-DM1) in patients with…
- Trial name
- NCT01983501
- Testing
- Tucatinib (ONT-380), T-DM1
- Where
- 11 sites in United States, Canada
- Volunteers
- 57 people
- Sponsor
- Seagen Inc.
Breast Cancer
Assessment of Breast Cancer-Related Arm Lymphedema
Lymphedema is a serious complication of breast cancer treatment. Reported prevalence of lymphedema following treatment for breast cancer varies, ranging from 7-45%.
- Trial name
- NCT03978754
- Testing
- ICG lymphography、CM、VD、Bioelectrical impedance technology、self-report, Bioelectrical impedance technology、CM
- Where
- China
- Volunteers
- 1,600 people
- Sponsor
- Peking University People's Hospital
Malignant Solid Tumour, Breast Cancer
Vaccine Therapy in Treating Patients With Metastatic Solid Tumors
This phase I trial studies the side effects and best dose of vaccine therapy in treating patients with metastatic solid tumors. Vaccines made from antibodies and peptides combined with tumor cells may help the body build an…
- Conditions
- Malignant Solid Tumour, Breast Cancer, Malignant Tumor of Colon, GIST
- Trial name
- NCT01376505
- Testing
- HER-2 vaccine, Extension HER-2 vaccine trial at OBD
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Robert Wesolowski
Metastatic or Locally-advanced Unresectable Breast Cancer
BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer
The purpose of this study is to test the safety of a drug called BYL719 at different dose levels. The investigators want to find out what effects, good and/or bad, BYL719 has on the patient and breast cancer.
- Trial name
- NCT01870505
- Testing
- BYL719, Letrozole, Exemestane
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Neoplasm Malignant Breast Tissue
What Factors Affect Breast Cancer Neoadjuvant Chemotherapy Efficacy?
Breast cancer is the most prevalent cancer affecting women. To treat locally advanced breast cancers, neoadjuvant chemotherapy (NACT) is often carried out before surgery to reduce the tumour size to allow breast conservation…
- Trial name
- NCT03501394
- Testing
- Magnetic Resonance Imaging, Histopathological Analysis, Health Questionnaire
- Where
- United Kingdom
- Volunteers
- 25 people
- Sponsor
- University of Aberdeen
Breast Cancer, PI3K/AKT/mTOR Pathway Mutation
Efficacy of Everolimus-containing Chemotherapy in HER2- mBC Patients With PI3K/AKT/mTOR Mutations Study
The study aimed to investigate the efficacy of the everolimus-containing chemotherapy in metastatic breast cancer patients with PI3K/AKT/mTOR mutations.14 cases of HER2- metastatic breast cancer patients with PI3K/AKT/mTOR…
- Conditions
- Breast Cancer, PI3K/AKT/mTOR Pathway Mutation, Everolimus
- Trial name
- NCT05054166
- Testing
- No intervention, it was a retrospective study.
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer
Follow-up in Early and Locally Advanced Breast Cancer Patients
A cross-sectional follow-up study of Early and Locally Advanced Breast Cancer patients after primary treatment.
- Trial name
- NCT03859453
- Where
- 28 sites in Belgium, France and 8 more
- Volunteers
- 830 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Neoplasm
Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer
The purpose of this study is to compare the objective response rates of patients randomized to receive either TOCOSOL(R) Paclitaxel or Taxol(R) (paclitaxel injection) administered every week to patients with metastatic breast…
- Trial name
- NCT00251095
- Testing
- Taxol, TOCOSOL Paclitaxel
- Where
- 14 sites in United States
- Volunteers
- 821 people
- Sponsor
- Achieve Life Sciences
Breast Cancer
Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer
The purpose of this study is to determine the effectiveness and safety of administering Herceptin in combination with Taxol (paclitaxel) in the treatment of women with HER2-positive, early stage breast cancer prior to surgery.
- Trial name
- NCT00136539
- Testing
- Herceptin, Taxol, Adriamycin
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- Harold J. Burstein, MD, PhD
Breast Cancer
ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer
This is a Phase II randomized, controlled, open label breast cancer clinical trial. 66 patients will be enrolled. The drugs being studied are hydroxychloroquine (Plaquenil) and abemaciclib (also Verzenio).
- Trial name
- ABBY (NCT04523857)
- Testing
- Abemaciclib, Hydroxychloroquine
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Breast Cancer
Exemestane With or Without ATN-224 in Treating Postmenopausal Women With Recurrent or Advanced Breast Cancer
RATIONALE: Exemestane may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. ATN-224 may stop the growth of breast cancer by blocking blood flow to the tumor.
- Trial name
- NCT00674557
- Testing
- SOD1 inhibitor ATN-224, exemestane, protein expression analysis
- Where
- United Kingdom
- Volunteers
- 111 people
- Sponsor
- Cancer Research UK
Breast Cancer
Multicenter Phase II Study of Apatinib in Patients With Advanced Breast Cancer(CABC006)
The treatment of the patients with recurrent and metastatic breast cancer remains a major problem. There is still a lack of effective targeted therapy for Her-2 negative breast cancer.Based on the present researches on the…
- Trial name
- NCT02878057
- Testing
- Apatinib
- Volunteers
- 30 people
- Sponsor
- Peking University Cancer Hospital & Institute
Recurrent Breast Carcinoma, Stage IV Breast Cancer
Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer
This phase II trial studies how well eribulin mesylate works in treating patients with previously treated breast cancer that has spread to other places in the body.
- Trial name
- NCT01908101
- Testing
- Eribulin Mesylate, Laboratory Biomarker Analysis
- Where
- 12 sites in United States
- Volunteers
- 86 people
- Sponsor
- University of Washington
Breast Cancer
Pilot Study of a MIND Diet Intervention in Women Undergoing Active Treatment for Breast Cancer
Breast cancer (BC) is the most frequently diagnosed cancer in women. Systemic cancer treatments are an important contributor to dramatic improvements in the long-term survival of women with BC.
- Trial name
- MIND-BC (NCT05984888)
- Testing
- MIND Diet Intervention Group, General Health Curriculum (GHC) Group
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Olanzapine, Breast Cancer
Olanzapine Based Dexamethasone-sparing Regimen for Breast Cancer Patients With Metabolic-risk Factors
The aim of THE STUDY to determine whether an olanzapine-based dexamethasone-sparing antiemetic regimen is non-inferior to the standard dexamethasone-containing regimen in preventing delayed-phase Chemotherapy-induced nausea and…
- Conditions
- Olanzapine, Breast Cancer, Dexamethasone
- Trial name
- NCT07743827
- Testing
- Pantoprazole, olanzapine, Dexamethasone
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Alexandria University
Breast Cancer
Optimizing Decision Making About Breast Reconstruction After Mastectomy: A Patient-Centered Approach
Although clinical decision tools (CDTs) exist for a variety of treatments, CDTs designed to support personalized breast reconstruction decisions, particularly about type and timing of reconstruction, are lacking.
- Trial name
- NCT03346161
- Testing
- Usual care American Society of Plastic Surgeons booklet "Breast Reconstruction", Decision tool, Usual Care Group - Outcome Measures
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Washington University School of Medicine
Breast Cancer
Characterizing Breast Cancer With 18F-FES PET/CT
18F-fluoroestradiol (FES) is radioactive labeled estradiol, developed for in vivo visualization of estrogen receptor (ER) using positron emission tomography (PET).
- Trial name
- NCT05613270
- Testing
- 18F-FES PET/CT scan
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking Union Medical College Hospital
Breast Cancer
Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer
The main objective of the trial is to determine the efficacy of doxorubicin-loaded anti-EGFR immunoliposomes as first-line therapy in patients with advanced triple Negative, EGFR positive breast cancer.
- Trial name
- NCT02833766
- Testing
- anti-EGFR-IL-dox
- Where
- 15 sites in Switzerland
- Volunteers
- 48 people
- Sponsor
- Swiss Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.